Division of Merck & Co. Inc.
Latest From Adolor Corp.
Five companies in big pharma’s top 20 have come through mergers in the past 10 years or so that changed them significantly. As measured by standard financial performance parameters, the processes at Takeda and Teva (and to some extent, at Allergan) seem relatively smooth and productive. Those at Pfizer and Merck don’t. But it depends on how you look at the numbers.
Relmada Therapeutics, Inc. has promoted Richard M. Mangano to chief scientific officer and Lisa Nolan to the newly created role of chief business officer. Mangano has experience leading R&D programs and previously held positions in discovery and clinical research at Hoffmann-La Roche, Lederle Laboratories, Wyeth Research, where he was acting therapeutic area director for neuroscience; and Adolor Corp., where he was vice-president of clinical research and development. Previously, Nolan was chief business officer at Topigen Pharmaceuticals, prior to this she was vice-president of global business development and strategic marketing for Skyepharma PLC. Nolan also held various senior positions in business and marketing at West Pharmaceutical Services, Elan Corp., and Zeneca Pharmaceuticals.
Hours after Merck revealed a merger agreement with Cubist, a court ruled that generic versions of Cubist’s big seller Cubicin can launch in 2016, two years earlier than expected, putting the pressure on Merck to justify the pricey acquisition.
Merck agreed to pay $9.5 billion to acquire Cubist, gaining a portfolio of antibiotics for hard-to-treat infections as part of a broader strategy to expand in the acute care setting.
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Merck & Co. Inc.
- Senior Management
Michael R Dougherty, Pres. & CEO
Kevin G Taylor, VP, Bus. Dev.
Michael D Adelman, VP, Mktg. & Sales
Richard M Mangano, PhD, VP, Clinical R&D
- Contact Info
Phone: (484) 595-1500
700 Pennsylvania Dr.
Exton, PA 19341